Back to search
FDAFDA · Food and drugs·Recall number Z-2085-2026

QUCARE Total Cholesterol in vitro diagnostic test REF: 6407

Published May 13, 2026 · Recall initiated: April 2, 2026

Summary

FDA records medical device Class II recall Z-2085-2026, published May 13, 2026 and initiated April 2, 2026. Recalling firm: DFI Co., Ltd.; Status: Ongoing; Reported quantity: 6398 units; Lot: UDI: 08806141303060/ Lot: BS032501, BS042502, BS062501, BS062502, BS082501. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The devices were distributed without required FDA premarket clearance or approval.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
DFI Co., Ltd.
Distributor
Worldwide - US Nationwide distribution in the states of FL, PA and the country of England.
Lot
UDI: 08806141303060/ Lot: BS032501, BS042502, BS062501, BS062502, BS082501
Risk classification
Class II
Area (FDA)
device
Country
Korea (the Republic of)

Related recalls

Questions about this recall

Was QUCARE Total Cholesterol in vitro diagnostic test REF: 6407 recalled?

Yes. FDA published recall Z-2085-2026 on May 13, 2026. Reported hazard: The devices were distributed without required FDA premarket clearance or approval.

What should I do if I have this product?

Voluntary: Firm initiated · Letter